Skip to Main Content

A year and a half ago, a Chinese company that many oncologists had never heard of wowed the cancer world with impressive early-stage data on its CAR-T cancer therapy in 35 Chinese patients with multiple myeloma. Johnson & Johnson quickly moved to license the therapy, and U.S. patients are starting to be dosed.

Next month, Legend Biotech is headed back into the spotlight. And this time it’s presenting data on 22 additional Chinese patients that raise more questions.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • going through mantle cell lymphoma a second time – the only cartcell clinical trials I found close to me (Oregon) were at oshu but they are no longer taking new patients – anything else close to Oregon that I might be able to do?

Comments are closed.